The estimated Net Worth of Yvonne Greenstreet is at least $35.8 Million dollars as of 20 August 2024. Yvonne Greenstreet owns over 15,000 units of Alnylam Pharmaceuticals Inc stock worth over $23,163,582 and over the last 11 years he sold ALNY stock worth over $9,405,744. In addition, he makes $3,250,030 as President and Chief Operating Officer at Alnylam Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Yvonne Greenstreet ALNY stock SEC Form 4 insiders trading
Yvonne has made over 17 trades of the Alnylam Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of ALNY stock worth $1,275,000 on 20 August 2024.
The largest trade he's ever made was exercising 57,811 units of Alnylam Pharmaceuticals Inc stock on 5 May 2020 worth over $4,184,938. On average, Yvonne trades about 3,542 units every 30 days since 2014. As of 20 August 2024 he still owns at least 88,441 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Yvonne Greenstreet stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Yvonne Greenstreet biography
Dr. Yvonne L. Greenstreet has been appointed as President, Chief Operating Officer of the Company effective 10/1/2020. She has served as the Company’s Chief Operating Officer since September 2016. Prior to joining the Company, Dr. Greenstreet most recently served as the founder and Managing Director of Highgate LLC, from January 2014 to August 2016. Prior to that time, Dr. Greenstreet served as the Senior Vice President and Head of Medicines Development at Pfizer Inc., a multinational pharmaceutical company, from December 2010 to November 2013. Prior to joining Pfizer, Dr. Greenstreet worked for 18 years at GlaxoSmithKline plc, or GSK, a multinational pharmaceutical, biologics, vaccines and consumer healthcare company, where she served in various positions, most recently as Senior Vice President and Chief of Strategy for Research and Development and as a member of GSK’s Product Management Board. Dr. Greenstreet currently serves on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation and serves as a director of Pacira Pharmaceuticals and American Funds.
What is the salary of Yvonne Greenstreet?
As the President and Chief Operating Officer of Alnylam Pharmaceuticals Inc, the total compensation of Yvonne Greenstreet at Alnylam Pharmaceuticals Inc is $3,250,030. There are 3 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.
How old is Yvonne Greenstreet?
Yvonne Greenstreet is 57, he's been the President and Chief Operating Officer of Alnylam Pharmaceuticals Inc since 2020. There are 15 older and 2 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.
What's Yvonne Greenstreet's mailing address?
Yvonne's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.
Insiders trading at Alnylam Pharmaceuticals Inc
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal, and Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
What does Alnylam Pharmaceuticals Inc do?
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
What does Alnylam Pharmaceuticals Inc's logo look like?
Complete history of Yvonne Greenstreet stock trades at Alnylam Pharmaceuticals Inc, Pacira BioSciences Inc, and Moelis & Co
Alnylam Pharmaceuticals Inc executives and stock owners
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
John Maraganore,
Chief Executive Officer, Director -
Jeffrey Poulton,
Chief Financial Officer, Executive Vice President -
Laurie Keating,
Executive Vice President, Chief Legal Officer, Secretary -
Yvonne Greenstreet,
President, Chief Operating Officer -
Akshay Vaishnaw,
President - Research and Development -
Dr. John M. Maraganore M.D., Ph.D.,
CEO & Exec. Director -
Margaret Hamburg,
Independent Director -
Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB,
Pres, COO & Director -
Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA,
Pres & COO -
Dr. Akshay K. Vaishnaw,
Pres of R&D -
Jeffrey V. Poulton M.B.A.,
CFO & Exec. VP -
Laurie Bartlett Keating J.D.,
Exec. VP, Chief Legal Officer & Sec. -
Michael Bonney,
Independent Chairman of the Board -
Phillip Sharp,
Independent Director -
Marsha Fanucci,
Independent Director -
Amy Schulman,
Independent Director -
Steven Paul,
Independent Director -
Colleen Reitan,
Independent Director -
David Pyott,
Independent Director -
Dennis Ausiello,
Independent Director -
Michael W. Bonney B.A.,
Exec. Chairman -
Olivier Brandicourt,
Director -
Kevin Fitzgerald,
Senior Vice President, Chief Scientific Officer -
Kelley Boucher,
Chief Human Resource Officer, Senior Vice President -
Arianna Greco,
Interim Chief Legal officer -
Mark Baglin,
VP of Global Marketing -
Agnieszka Gallagher,
Chief Ethics & Compliance Officer -
Christine Regan Lindenboom,
Sr. VP of Investor Relations & Corp. Communications -
Dr. Alfred W. Boyle Ph.D.,
Chief Technical Operations & Quality Officer -
David Alexandre C Gros,
SVP, Chief Business Officer -
Kevin P Starr,
Director -
Paul Schimmel,
Director -
Sanofi,
10% owner -
Michael Mason,
VP, Finance and Treasurer -
John K Clarke,
Director -
Barry E Greene,
President -
Manmeet Singh Soni,
Chief Financial Officer -
Carolyn R Bertozzi,
Director -
Pushkal Garg,
CMO & EVP Dev & Med Affairs -
Peter N Kellogg,
Director -
Venture Management Co Iii L...,
10% owner -
Victor J Dzau,
Director -
Agnovartis Pharma Ag Novartis,
-
Venture Management Co Iii L...,
-
Peter Barrett,
Director -
Christoph H Westphal,
Director -
Venture Fund V Lpatlas Vent...,
-
Venture Management Co Iii L...,
-
Ii Lp Chp,
10% owner -
Kenneth S Koblan,
Chief Scientific Officer -
Laurence Reid,
SVP, Chief Business Officer -
Vicki L Sato,
Director -
Management Ltd Abingworth,
10% owner -
John A Jr Schmidt,
SVP, Chief Scientific Officer -
Patricia L Allen,
VP Finance and Treasurer -
Venture Fund V Lpatlas Vent...,
-
John E Berriman,
Director -
Vincent J Miles,
Senior VP Business Development -
James L Vincent,
Director -
Venture Fund V Lpatlas Vent...,
-
Edward M Scolnick,
Director -
Tolga Tanguler,
EVP, Chief Commercial Officer -
Charles Elliott Sigal,
Director